Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Nicola Giuliani

Cattedra di Ematologia e CTMO

Universita Degli Studi di Parma

Parma

Italy

[email]@unipr.it

Name/email consistency: high

[Claim this account]

Affiliations

Cattedra di Ematologia e CTMO, Universita Degli Studi di Parma, Parma, Italy. 2007 - 2009
Hematology and Bone Marrow Transplantation Center, University of Parma, Parma, Italy. 2008
Hematology and Bone Marrow Transplantation Center, Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy. 2002 - 2008
Cattedra e Unità Operativa (UO) di Ematologia-Centro Trapianti Midollo Osseo (CTMO), Università Degli Studi di Parma, Italy. 2006
Chair of Hematology, BMT Unit, University of Parma, Italy. 2004
University of Parma, Parma, Italy. 2004

References

Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Giuliani, N., Mangoni, M., Rizzoli, V. Exp. Hematol. (2009) [Pubmed]
CC-Chemokine ligand 20/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Giuliani, N., Lisignoli, G., Colla, S., Lazzaretti, M., Storti, P., Mancini, C., Bonomini, S., Manferdini, C., Codeluppi, K., Facchini, A., Rizzoli, V. Cancer Res. (2008) [Pubmed]
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Bonomini, S., Crugnola, M., Mancini, C., Martella, E., Ferrari, L., Tabilio, A., Rizzoli, V. Blood (2007) [Pubmed]
Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Giuliani, N., Rizzoli, V. Leuk. Lymphoma (2007) [Pubmed]
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Giuliani, N., Rizzoli, V., Roodman, G.D. Blood (2006) [Pubmed]
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S., Svaldi, M., Rizzoli, V. Blood (2005) [Pubmed]
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Giuliani, N., Lunghi, P., Morandi, F., Colla, S., Bonomini, S., Hojden, M., Rizzoli, V., Bonati, A. Leukemia (2004) [Pubmed]
New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Giuliani, N., Colla, S., Rizzoli, V. Exp. Hematol. (2004) [Pubmed]
Update on the pathogenesis of osteolysis in multiple myeloma patients. Giuliani, N., Colla, S., Rizzoli, V. Acta. Bio-medica. :. Atenei. Parmensis (2004) [Pubmed]
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Giuliani, N., Colla, S., Sala, R., Moroni, M., Lazzaretti, M., La Monica, S., Bonomini, S., Hojden, M., Sammarelli, G., Barillè, S., Bataille, R., Rizzoli, V. Blood (2002) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.